Literature DB >> 10421646

Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization.

W R Kim1, R H Wiesner, J J Poterucha, T M Therneau, M Malinchoc, J T Benson, J S Crippin, G B Klintmalm, J Rakela, T E Starzl, R A Krom, R W Evans, E R Dickson.   

Abstract

The aim of our study was to quantitatively assess the impact of hepatic retransplantation on patient and graft survival and resource utilization. We studied patients undergoing hepatic retransplantation among 447 transplant recipients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) at 3 transplantation centers. Cox proportional hazards regression analysis was used for survival analysis. Measures of resource utilization included the duration of hospitalization, length of stay in the intensive care unit, and the duration of transplantation surgery. Forty-six (10.3%) patients received 2 or more grafts during the follow-up period (median, 2.8 years). Patients who underwent retransplantation had a 3.8-fold increase in the risk of death compared with those without retransplantation (P <.01). Retransplantation after an interval of greater than 30 days from the primary graft was associated with a 6.7-fold increase in the risk of death (P <.01). The survival following retransplantations performed 30 days or earlier was similar to primary transplantations. Resource utilization was higher in patients who underwent multiple consecutive transplantations, even after adjustment for the number of grafts during the hospitalization. Among cholestatic liver disease patients, poor survival following hepatic retransplantation is attributed to late retransplantations, namely those performed more than 30 days after the initial transplantation. While efforts must be made to improve the outcome following retransplantation, a more critical evaluation may be warranted for late retransplantation candidates.

Entities:  

Mesh:

Year:  1999        PMID: 10421646      PMCID: PMC2957088          DOI: 10.1002/hep.510300210

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Hepatic Retransplantation.

Authors:  B W Shaw; R D Gordon; S Iwatsuki; T E Starzl
Journal:  Transplant Proc       Date:  1985-02       Impact factor: 1.066

2.  Primary nonfunction of the liver graft: when should we retransplant?

Authors:  G S Kamath; D J Plevak; R H Wiesner; S R Rettke; B Myers; J Ludwig; R A Krom
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

3.  Results after liver retransplantation (RETx): a comparative study between "elective" vs "nonelective" RETx.

Authors:  N P Mora; G B Klintmalm; J B Cofer; S S Poplawski; R M Goldstein; T A Gonwa; B S Husberg
Journal:  Transplant Proc       Date:  1990-08       Impact factor: 1.066

4.  A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease.

Authors:  P Ricci; T M Therneau; M Malinchoc; J T Benson; J L Petz; G B Klintmalm; J S Crippin; R H Wiesner; J L Steers; J Rakela; T E Starzl; E R Dickson
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

Review 5.  Liver transplantation (2).

Authors:  T E Starzl; A J Demetris; D Van Thiel
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

6.  Comparison of perioperative morbidity following primary liver transplantation and liver retransplantation.

Authors:  H P Lemmens; N Tsiblakis; J M Langrehr; G Blumhardt; R Lohmann; H Keck; P Neuhaus
Journal:  Transplant Proc       Date:  1993-04       Impact factor: 1.066

7.  Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted?

Authors:  H R Doyle; I R Marino; N Jabbour; G Zetti; J McMichael; S Mitchell; J Fung; T E Starzl
Journal:  Transplantation       Date:  1994-04-15       Impact factor: 4.939

8.  Risk factors for primary dysfunction after liver transplantation--a multivariate analysis.

Authors:  R J Ploeg; A M D'Alessandro; S J Knechtle; M D Stegall; J D Pirsch; R M Hoffmann; T Sasaki; H W Sollinger; F O Belzer; M Kalayoglu
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

9.  Primary sclerosing cholangitis: refinement and validation of survival models.

Authors:  E R Dickson; P A Murtaugh; R H Wiesner; P M Grambsch; T R Fleming; J Ludwig; N F LaRusso; M Malinchoc; R W Chapman; M M Kaplan
Journal:  Gastroenterology       Date:  1992-12       Impact factor: 22.682

10.  Trends in liver transplantation in the United States.

Authors:  S H Belle; K C Beringer; K M Detre
Journal:  Clin Transpl       Date:  1993
View more
  3 in total

1.  Decision for retransplantation of the liver: an experience- and cost-based analysis.

Authors:  Daniel Azoulay; Marcello M Linhares; Emmanuel Huguet; Valérie Delvart; Denis Castaing; René Adam; Philippe Ichai; Faouzi Saliba; Antoinette Lemoine; Didier Samuel; Henri Bismuth
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

2.  Outcomes of liver retransplantation in patients with primary sclerosing cholangitis.

Authors:  Jacqueline B Henson; Yuval A Patel; Lindsay Y King; Jiayin Zheng; Shein-Chung Chow; Andrew J Muir
Journal:  Liver Transpl       Date:  2017-06       Impact factor: 5.799

3.  Significant influence of the primary liver disease on the outcomes of hepatic retransplantation.

Authors:  A Qasim; B M Zaman; J Geoghegan; D Maguire; O Traynor; J Hegarty; P A McCormick
Journal:  Ir J Med Sci       Date:  2008-11-04       Impact factor: 1.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.